androgen deprivation therapy

Phase 3Small molecule

androgen deprivation therapy is one of 198 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

197

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Prostate CancerRecruiting

Cardiovascular DiseaseActive, not recruiting

Androgen Axis SuppressionRecruiting

Reccurent/metastatic Solid Tumor DiseaseRecruiting

Prostatic NeoplasmsActive, not recruiting

Prostate Cancer (adenocarcinoma)Recruiting

Castration Levels of TestosteroneActive, not recruiting

Hormone Sensitive Prostate CancerActive, not recruiting

MetastasesNot yet recruiting

Radiation TherapyRecruiting

Metastatic Prostate CancerPhase 3

Recruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

Androgen Axis SuppressionPhase 3

Recruiting

Reccurent/metastatic Solid Tumor DiseasePreclinical

Recruiting

Prostatic NeoplasmsPhase 3

Active, not recruiting

Prostate Cancer (adenocarcinoma)Preclinical

Recruiting

Castration Levels of TestosteronePhase 2

Active, not recruiting

Hormone Sensitive Prostate CancerPhase 2

Active, not recruiting

MetastasesPhase 2

Not yet recruiting

Radiation TherapyPhase 3

Recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

26 2

Opdivo

Bristol-Myers Squibb

Phase 3

22 3

Lupron

EEastern Cooperative Oncology Group

Phase 3

53 4

Talzenna

Pfizer

Phase 3

9 5

Tecentriq

Roche

Phase 3

8 6

Ritalin

Novartis

Phase 3

2 7

androgen deprivation therapy

Johnson & Johnson

Phase 3

48 8

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

4 9

Antibiotic

Pfizer

Phase 3

1 10

Trexall

Jazz Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Prostate Cancer

NCT05100472

Phase 2Active, not recruiting

Hormone Sensitive Prostate Cancer

NCT04126070

Phase 2Not yet recruiting

Recurrence

NCT05778097

Phase 2Active, not recruiting

Prostate Cancer

NCT03569241

Phase 2Not yet recruiting

Metastases

NCT05717582

Q1 2027

N/AActive, not recruiting

Prostate Cancer

NCT02296229

Clinical

Trials by Indication[1]

Prostate Cancer48 trials

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

Unknown status·FFudan University·Phase 2·NCT05223582·34 enrolled

Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02217566·46 enrolled

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT05753566·96 enrolled

Show 45 more trials

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

Recruiting·UUniversity College, London·Phase 3·NCT06320067·3,360 enrolled

Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT00242567·522 enrolled

Radiation and Androgen Ablation for Prostate Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT01517451·45 enrolled

Radiotherapy After Prostatectomy for Node Positive Prostate Cancer

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT07477626·374 enrolled

Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer

Terminated·UUniversity of Alabama at Birmingham·Phase 2·NCT04298983·9 enrolled

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Completed·PPedro Barata, MD, MSc·Phase 2·NCT06312670·13 enrolled

Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation

Recruiting·UUniversity of Chicago·Phase 2·NCT05790213·57 enrolled

Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT

Active, not recruiting·IIstituto Clinico Humanitas·N/A·NCT04624828·40 enrolled

Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT06305832·102 enrolled

Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis

Unknown status·EEuropean Institute of Oncology·Phase 2·NCT03940235·150 enrolled

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

Recruiting·UUniversity of Miami·Phase 2·NCT06392295·34 enrolled

Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.

Not yet recruiting·QQilu Hospital of Shandong University·Phase 2·NCT06500247·43 enrolled

Outcome Of Treatment Of Prostate Cancer at Sohag University Hospital Between 2017 to 2021

Unknown status·SSohag University··NCT05382182·100 enrolled

Efficacy Study Evaluating Chemotherapy in Prostate Cancer

Unknown status·ÖÖrebro University, Sweden·Phase 3·NCT01978873·400 enrolled

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04191096·1,251 enrolled

Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer

Active, not recruiting·JJonsson Comprehensive Cancer Center·N/A·NCT02296229·220 enrolled

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT04034095·979 enrolled

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer

Recruiting·UUniversity of Virginia·Phase 2·NCT04465500·60 enrolled

Implementation of Precision Medicine in High-risk Prostate Cancer

Recruiting·AAndreas Josefsson··NCT06687421·5,500 enrolled

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Completed·—·Phase 2·NCT00776594·102 enrolled

Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer

Terminated·DDavid VanderWeele·Phase 1/2·NCT04737109·6 enrolled

PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases

Active, not recruiting·UUniversity Hospital, Ghent·Phase 2·NCT03569241·196 enrolled

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05100472·50 enrolled

CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer

Not yet recruiting·FFudan University·Phase 2·NCT07268794·112 enrolled

Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

Unknown status·VVA Greater Los Angeles Healthcare System·Phase 2·NCT04489745·72 enrolled

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 3·NCT05352178·873 enrolled

Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer

Terminated·TThe Netherlands Cancer Institute·Phase 1·NCT03066154·24 enrolled

Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer

Active, not recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT05477823·30 enrolled

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00079001·645 enrolled

ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer

Withdrawn·WWeill Medical College of Cornell University·Phase 1·NCT05567770

A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02).

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06952803·700 enrolled

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Preclinical·NCT03543189·44 enrolled

Prostate-only, Dose-escalated Radiotherapy Plus Concomitant Androgen Deprivation Therapy in Primary Localized, NCCN High Risk and MMAI Classifier Low or Intermediate-risk Prostate Cancer - A Prospective, Single-arm, Phase II Study

Recruiting·GGerman Oncology Center, Cyprus·Phase 2·NCT06772441·30 enrolled

Metastasis-directed Radiotherapy (MDRT) for Men With De-novo Oligometastatic Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

Recruiting·CCase Comprehensive Cancer Center·Phase 2·NCT06150417·200 enrolled

A Phase II Prospective Trial Utilizing Short Course Androgen Deprivation Therapy In Conjunction With Ultra-Hypofractionated SBRT For High Risk Nccn Prostate Cancer With Lower Risk Artera Scores

Recruiting·NNYU Langone Health·Phase 2·NCT07801664·90 enrolled

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Active, not recruiting·AAragon Pharmaceuticals, Inc.·Phase 3·NCT02489318·1,052 enrolled

Abiraterone/Prednisone + Standard ADT vs Standard ADT for Prostate Cancer Patients With PSMA-Positive Conventional Imaging Negative Pelvic Lymphadenopathy

Recruiting·UUniversity of Nebraska·Phase 2·NCT07237269·140 enrolled

Establishing a Neo-Adjuvant Platform for Developing Targeted Agents: Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT01542021·41 enrolled

Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)

Active, not recruiting·SSir Mortimer B. Davis - Jewish General Hospital·Phase 3·NCT02303327·307 enrolled

PRO-BOOST-N: A Randomized Phase II/III Trial Evaluating Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer Using an Ultrahypofractionated Whole-Pelvis Radiotherapy Platform

Recruiting·AAffidea Nu-med Center of Oncological DIagnostics and Therapy·Preclinical·NCT07426094·600 enrolled

Phase II Study of Pembrolizumab in Combination With Radiation With or Without Olaparib in Localized High-risk Prostate Cancer

Recruiting·ZZin W Myint·Phase 2·NCT05568550·64 enrolled

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, ADT, Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON): A Phase II, Single Arm, Single Institution Study

Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT04748042·21 enrolled

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

Active, not recruiting·WWashington University School of Medicine·Preclinical·NCT05628363·28 enrolled

A Single-arm, Open-label Phase 2 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy (ADT) in Chinese Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Completed· Bayer logo

Bayer·Phase 2·NCT05171387·78 enrolled

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT07313241·68 enrolled

Metastatic Prostate Cancer3 trials

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Completed·EECOG-ACRIN Cancer Research Group·Phase 3·NCT00309985·790 enrolled

High-Risk Metachronous Oligometastatic Prostate Cancer Trial

Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT06212583·88 enrolled

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Recruiting·UUNICANCER·Phase 3·NCT04916613·300 enrolled

Prostatic Neoplasms3 trials

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT03767244·2,517 enrolled

PEACE-9 - ESCALATE-RT: A Phase III Randomized Study in Patients With High-risk PSA Relapse After Local Therapy Treated With Enzalutamide Plus Androgen Deprivation Therapy and Comparing MDT ± Pelvic Radiotherapy Versus no Further Treatment

Not yet recruiting·EEnte Ospedaliero Cantonale, Bellinzona·Phase 3·NCT07782112·140 enrolled

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)

Completed· Johnson & Johnson logo

Johnson & Johnson·Approved·NCT04108208·75 enrolled

Metastatic Hormone Sensitive Prostate Cancer2 trials

China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Active, not recruiting· Astellas logo

Astellas·Phase 3·NCT04076059·180 enrolled

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT04934722·186 enrolled

Prostate Carcinoma2 trials

A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT05884398·420 enrolled

Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)

Recruiting·NNYU Langone Health·Preclinical·NCT07142967·28 enrolled

18 more indications

Cardiovascular Disease1 trial

Prospective Study of Insulin Resistance and Cardiovascular Disease Risk During Androgen Deprivation Therapy for Prostate Cancer

Completed·MMassachusetts General Hospital··NCT00455624·60 enrolled

Recurrence1 trial

Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)

Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT05778097·103 enrolled

Prostatectomy1 trial

Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy

Active, not recruiting·IInsel Gruppe AG, University Hospital Bern·N/A·NCT05746806·36 enrolled

First Line Therapy1 trial

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

Completed·FFirst Affiliated Hospital of Wenzhou Medical University··NCT07428642·168 enrolled

Liquid Biopsy1 trial

Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial

Unknown status·FFudan University··NCT05188911·30 enrolled

Radiation Therapy1 trial

Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging

Recruiting·UUNICANCER·Phase 3·NCT06276465·336 enrolled

Abiraterone Acetate1 trial

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Withdrawn·QQian Qin·Phase 2·NCT06392841

Exercise1 trial

EXTEND Exercise Trial

Completed·—·Phase 2·NCT02256111·26 enrolled

Metastases1 trial

Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment

Not yet recruiting·FFudan University·Phase 2·NCT05717582·47 enrolled

Metastatic Castration-resistant Prostate Cancer, mCRPC1 trial

An Open-label, Multi-center, First in Human Phase I Global Dose Escalation and Expansion Study of INR731 Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer

Recruiting· Novartis logo

Novartis·Phase 1·NCT07570979·208 enrolled

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)1 trial

A Multicenter, Prospective, Randomized Controlled Phase II Trial of PSMA PET/CT-Guided Stereotactic Body Radiotherapy Combined With Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Not yet recruiting·WWest China Hospital·Phase 2·NCT07649421·254 enrolled

Hormone Sensitive Prostate Cancer1 trial

A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed Tumors

Active, not recruiting·XXiao X. Wei, MD·Phase 2·NCT04126070·47 enrolled

Castration Levels of Testosterone1 trial

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Active, not recruiting·EECOG-ACRIN Cancer Research Group·Phase 2·NCT03419234·223 enrolled

Androgen Axis Suppression1 trial

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Recruiting·MM.D. Anderson Cancer Center·Phase 3·NCT06274047·120 enrolled

Prostate Cancer (Adenocarcinoma)1 trial

PRO-BOOST-LC: A Prospective, Multi-arm Phase II/III Clinical Trial Evaluating the Efficacy and Safety of Whole-Gland Boost Using HDR Brachytherapy, LDR Brachytherapy, or Single-Fraction SBRT Following an Ultrahypofractionated EBRT (VMAT) Backbone (5 Gy x 5 Fractions) Compared to Standard SBRT Monotherapy in Patients With Localized and Locally Advanced Prostate Cancer Staged With PSMA PET/CT

Recruiting·AAffidea Nu-med Center of Oncological DIagnostics and Therapy·Preclinical·NCT07426055·1,000 enrolled

Prostate Adenocarcinoma1 trial

RAD 2003/XUAB2104: Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

Completed·AAndrew McDonald·Phase 2·NCT04743934·44 enrolled

Reccurent/Metastatic Solid Tumor Disease1 trial

Non-Inferiority Study Comparing Hypofractionated Post-Operative Salvage Radiotherapy Regimens: 45/62.5 Gy in 25 Fractions vs. 43/52.5 Gy in 20 Fractions for Grade 2+ GU or GI Toxicity (HYP-OP-RT)

Recruiting·CCHU de Quebec-Universite Laval·Preclinical·NCT07483658·434 enrolled

Metastatic Castration-Resistant Prostate Cancer1 trial

A Multicenter Phase 4, Open-label, Single-arm, Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Completed· Astellas logo

Astellas·Approved·NCT03641560·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 76 trial records for androgen deprivation therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — androgen deprivation therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for androgen deprivation therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

androgen deprivation therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Prostate Cancer48 trials

Metastatic Prostate Cancer3 trials

Prostatic Neoplasms3 trials

Metastatic Hormone Sensitive Prostate Cancer2 trials

Prostate Carcinoma2 trials

Cardiovascular Disease1 trial

Recurrence1 trial

Prostatectomy1 trial

First Line Therapy1 trial

Liquid Biopsy1 trial

Radiation Therapy1 trial

Abiraterone Acetate1 trial

Exercise1 trial

Metastases1 trial

Metastatic Castration-resistant Prostate Cancer, mCRPC1 trial

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)1 trial

Hormone Sensitive Prostate Cancer1 trial

Castration Levels of Testosterone1 trial

Androgen Axis Suppression1 trial

Prostate Cancer (Adenocarcinoma)1 trial

Prostate Adenocarcinoma1 trial

Reccurent/Metastatic Solid Tumor Disease1 trial

Metastatic Castration-Resistant Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News